

[Generate Collection](#)[Print](#)*Prior Art Search***Search Results - Record(s) 101 through 114 of 114 returned.**

-
- ☐ 101. [US 20050287150 A1](#). New human monoclonal **antibody** or its antigen binding portion that specifically binds to an exotoxin of *Clostridium difficile*, useful in preparing a composition for treating a *Clostridium difficile*-associated disorder in a mammal. AMBROSINO D, et al.
-
- ☐ 102. [WO 2005037312 A2](#). Detection of atherosclerotic plaques, using binding molecules specific for the extra-B domain of fibronectin, also useful for preventing, e.g. cardiac infarction and angina pectoris. HELDMANN D.
-
- ☐ 103. [WO 2005023318 A1](#). Specific binding component that binds human **ED-B**, labeled with isotope and comprising antigen-binding site that comprises **antibody VH and VL** domain, useful in manufacture of medicament for treating lesion of angiogenesis or tumor. BALZA E, et al.
-
- ☐ 104. [EP 1514561 A1](#). New isotopically labeled specific binding member that binds human **ED-B**, useful for manufacturing a medicament for treating a lesion of pathological angiogenesis, tumor, or for manufacturing a diagnostic reagent. BALZA E, et al.
-
- ☐ 105. [WO 2004026326 A2](#). Treating subject exposed to microorganism binding to Dendritic cell-specific intercellular adhesion molecules-grabbing non-integrin (DC-SIGN), by administering compound to inhibit binding of microorganisms to DC-SIGN. FIGDOR C G, et al.
-
- ☐ 106. [WO 03076469 A2](#). New specific binding member that binds human **ED-B** and comprises an antigen-binding site consisting of **antibody VH and VL** domains, useful for preparing a composition for treating tumors or a lesion of pathological angiogenesis. BALZA E, et al.
-
- ☐ 107. [WO 03055917 A2](#). Novel compound which comprises a peptide that is a derivative of recombinant **scFv antibody L19** against the extra domain B of fibronectin, useful for binding a radioisotope, preferably ^{99m}Tc or ¹⁸⁸Re. BERNDORFF D, et al.
-
- ☐ 108. [WO 03048334 A2](#). New fusion protein comprising a non-IL-2 moiety fused to a mutant IL-2 moiety, useful for preparing a composition for treating cancer, viral infections or immune disorders. GILLIES S, et al.
-
- ☐ 109. [US 20030022254 A1](#). Novel purified mammalian transcription factor regulatory protein useful for treating actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, psoriasis, and cancers. BAUGHN M R, et al.
-
- ☐ 110. [WO 0197850 A2](#). Novel composition useful for treating cancer, comprises agents interfering with vascular endothelial growth factor/VEGF receptor system activity and agents interfering with Angiopoietin/Tie receptor system function. HABEREY M, et al.
-
- ☐ 111. [WO 0181389 A1](#). Human protein 9 containing characteristic fragment of ribosomal protein **L19** and encoded polynucleotide, applicable in diagnosis and treatment of cancer, hemopathy, HIV infection, immunological diseases and inflammation. MAO Y, et al.
-

☐ 112. WO 0123005 A1. New **antibody**-dye conjugates that accumulate at edges of disease foci, useful for depicting edges of tumors during surgery to facilitate complete removal. DINKELBORG L, et al.

☐ 113. WO 0063251 A1. Methods for modulating dendritic cell and T cell interaction by using a compound, such as mannose carbohydrates, that binds to a C-type lectin on a dendritic cell surface, useful in the treatment of autoimmune diseases and allergy. FIGDOR C, et al.

☐ 114. WO 9959629 A1. Humanized **antibody** binding to verotoxin II used for treating Verotoxin producing E. coli. BASQUES M, et al.

[Generate Collection](#)[Print](#)

Term	Documents
L19	3200
L-19	3303
((L-19 OR L19) AND 10).PGPB,USPT,USOC,EPAB,JPAB,DWPL	114
(L10 and ("L19" or "L-19")).PGPB,USPT,USOC,EPAB,JPAB,DWPL	114

[Prev Page](#)[Next Page](#)[Go to Doc#](#)